BALAXI PHARMA LTD vs Laurus Labs Limited

A side-by-side comparison of BALAXI PHARMA LTD (BALAXI) and Laurus Labs Limited (LAURUSLABS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Laurus Labs Limited leads BALAXI vs LAURUSLABS on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation31
  • Profitability04
  • Growth02
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

BALAXI takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

85.35
P/E ratio
125.08
0.52
P/B ratio
19.74
2.15%
Dividend yield
0.10%
₹0.26
EPS
₹16.47

Profitability

LAURUSLABS takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

0.57%
Return on equity
16.77%
3.00%
Return on capital
17.58%
3.16%
EBITDA margin
26.09%
0.52%
Net margin
13.07%

Growth

LAURUSLABS takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-7.01%
Revenue CAGR (3Y)
4.09%
-68.63%
Profit CAGR (3Y)
3.91%

Size & financial health

LAURUSLABS takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹122 Cr
Market cap
₹1.11L Cr
₹270 Cr
Revenue
₹6,813 Cr
₹1 Cr
Net profit
₹890 Cr
0.23
Debt / equity
0.45
BALAXI PHARMA LTD
  • + ["Stock is trading at 0.49 times its book value"]
  • − ["The company has delivered a poor sales growth of 3.2% over past five years.", "The company has delivered a poor profit growth of -48.2% over past five years.", "Company has a low return on equity of 3.7% over last 3 years."]
Laurus Labs Limited
  • + []
  • − ["Stock is trading at 21.00 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
BALAXI PHARMA LTD full analysis Laurus Labs Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.